Catalyst Pharmaceuticals, Inc. $CPRX Shares Purchased by Hsbc Holdings PLC

Hsbc Holdings PLC raised its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 91.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 57,929 shares of the biopharmaceutical company’s stock after buying an additional 27,739 shares during the period. Hsbc Holdings PLC’s holdings in Catalyst Pharmaceuticals were worth $1,362,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Smartleaf Asset Management LLC raised its position in Catalyst Pharmaceuticals by 55.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 630 shares in the last quarter. Clearstead Advisors LLC boosted its position in Catalyst Pharmaceuticals by 192.9% in the 4th quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 1,167 shares in the last quarter. Larson Financial Group LLC grew its stake in shares of Catalyst Pharmaceuticals by 552.7% during the 4th quarter. Larson Financial Group LLC now owns 1,847 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 1,564 shares during the period. Advisory Services Network LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the 3rd quarter worth approximately $39,000. Finally, Quarry LP acquired a new position in shares of Catalyst Pharmaceuticals in the 3rd quarter valued at $40,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Wall Street Analysts Forecast Growth

CPRX has been the topic of a number of recent analyst reports. Zacks Research downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, May 18th. Citigroup cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the company from $35.00 to $31.50 in a report on Friday, May 8th. Robert W. Baird downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. Oppenheimer lowered shares of Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 7th. Finally, Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Friday, March 27th. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, Catalyst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Catalyst Pharmaceuticals Stock Up 0.0%

Shares of NASDAQ:CPRX opened at $31.44 on Thursday. Catalyst Pharmaceuticals, Inc. has a 52-week low of $19.05 and a 52-week high of $32.56. The business has a fifty day moving average of $30.71 and a two-hundred day moving average of $26.41. The stock has a market cap of $3.85 billion, a P/E ratio of 18.07, a PEG ratio of 0.95 and a beta of 0.74.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).